Travere Therapeutics, Inc. TVTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $490.73M+110% | $233.18M+60.5% | $145.24M+32.7% | $109.46M— | ||
| $10.34M+33.5% | $7.74M-32.4% | $11.45M+85.5% | $6.17M— | ||
| $480.39M+113% | $225.43M+68.5% | $133.79M+29.5% | $103.29M— | ||
| 97.9%+1.2pp | 96.7%+4.6pp | 92.1%-2.2pp | 94.4%— | ||
| $206.01M-5.3% | $217.5M-11.2% | $244.99M+5.8% | $231.52M+15.1% | ||
| $324.78M+23.0% | $264.12M-0.5% | $265.54M+26.9% | $209.27M+65.7% | ||
| $553.55M-0.6% | $557M+4.4% | $533.38M+24.3% | $429.27M+29.6% | ||
| -$62.82M+80.6% | -$323.83M+16.6% | -$388.14M-21.4% | -$319.81M-60.4% | ||
| -12.8%+126pp | -138.9%+128pp | -267.2%+24.9pp | -292.2%— | ||
| $10.75M-3.9% | $11.18M+98.4% | $5.64M-48.1% | $10.85M+155% | ||
| $12.72M-28.6% | $17.82M-18.2% | $21.77M+247% | $6.28M+215% | ||
| $13.55M+308% | $3.32M-72.4% | $12.03M— | —— | ||
| -$49.27M+84.6% | -$320.51M+14.8% | -$376.11M-13.6% | -$331.16M-52.7% | ||
| $988K— | —— | $223K-28.8% | $313K-23.5% | ||
| —— | -$321.55M-189% | -$111.4M+60.0% | -$278.48M-54.6% | ||
| —— | —— | -$191.17M-3,690,598,405% | -$5.18-42.7% | ||
| —— | -$4.08-153% | -$1.61+63.2% | -$4.37-44.2% | ||
| —— | -$4.08-153% | -$1.61+63.2% | -$4.37-44.2% | ||
| 369.1M+18.6% | 311.3M+5.6% | 294.7M+15.8% | 254.6M+7.2% | ||
| 355.7M+14.3% | 311.3M+5.6% | 294.7M+15.8% | 254.6M+7.2% | ||
| —— | —— | —— | —— | ||
| -$29.25M+90.9% | -$320.17M-191% | -$109.95M+60.8% | -$280.83M-56.2% | ||
| -$50.26M+84.3% | -$320.63M+14.8% | -$376.33M-13.5% | -$331.47M-52.5% | ||
| $11.58M+449% | -$3.32M-308% | $1.6M+63.8% | $974K+322% | ||
| $206.01M-5.3% | $217.5M-11.2% | $244.99M+5.8% | $231.52M+15.1% | ||
| $490.73M+110% | $233.18M+60.5% | $145.24M+32.7% | $109.46M— | ||
| -$62.82M+80.6% | -$323.83M+16.6% | -$388.14M-21.4% | -$319.81M-60.4% | ||
| -$2.08M+99.3% | -$280.27M+19.8% | -$349.61M-17.2% | -$298.3M— | ||
| -$2.08M+99.3% | -$280.27M+19.8% | -$349.61M-17.2% | -$298.3M— | ||
| -0.4%+120pp | -120.2%+121pp | -240.7%+31.8pp | -272.5%— | ||
| -$62.82M+80.6% | -$323.83M+16.6% | -$388.14M-21.4% | -$319.81M-60.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Travere Therapeutics, Inc.'s profit margins?
- Gross margin is 98.6% and operating margin is -10.6%, with a -20.3% net margin.
- Where does Travere Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.